Brief Report of Anti–Programmed Cell Death Protein-1 in Human Immunodeficiency Virus Setting: Relevant and Breaking Results in First-Line NSCLC Therapy
In the recent past, we observed an increased risk of cancer in the population with human immunodeficiency virus (HIV) owing to the development of antiretroviral therapies that decreased mortality caused by HIV-specific infections. This particularly fragile population is frequently excluded from clin...
Guardado en:
Autores principales: | Lise Bertin, MD, Anthony Canellas, MD, Baptiste Abbar, MD, Marianne Veyri, Jean-Philippe Spano, MD, PhD, Jacques Cadranel, MD, PhD, Armelle Lavolé, MD |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ec6f4644ae4240f5bb7de65702a720dc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
por: Jean-Louis Pujol, MD, PhD, et al.
Publicado: (2021) -
MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Katsuhiro Yoshimura, MD, PhD, et al.
Publicado: (2021) -
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Liesbeth M. Hondelink, MD, et al.
Publicado: (2021) -
Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC
por: Santosh K. Patnaik, MD, PhD, et al.
Publicado: (2021) -
The Results of Pars Plana Vitrectomy in the Treatment of Intraocular Retinoblastoma: A Retrospective Study and Literature Review
por: Lu Li MD, PhD, et al.
Publicado: (2021)